P4pal10

P4pal10

Catalog Number:
P004516884LIF
Mfr. No.:
PEPTIDE-PR-100
Price:
$301
  • Size:
    1mg
    Quantity:
    Add to Cart:
      • Overview
        • PAR4 antagonist.
          P4pal10 is a pepducin with a peptide sequence identical to part of the third intracellular loop of the protease activated receptor 4 (PAR4) which acts as a PAR4 antagonist. P4pal10 has no agonist activity as measured by platelet aggregation, intracellular Ca2+ release or InsP production, but preincubation of human platelets with P4pal10 completely blocks aggregation in response to PAR4 activators. Infusion of P4Pal10 into mice extends bleeding time and protects against systemic platelet activation, and in rat models of myocardial injury, P4pal10 treatment before ischemia significantly decreases infarct size when given before, during, and after ischemia. P4Pal10 also inhibits signalling downstream of the Gi-coupled FPR2.

          Please contact us for availability.

          Please contact us at for specific academic pricing.

      • Properties
        • Categories
          Peptides
          Alternative Name
          Pepducin P4Pal10, palmitoyl-SGRRYGHALR-amide, P4pal-10
          Molecular Formula
          C65H112N22O13
          Molecular Weight
          1409.72
          Appearance
          Freeze dried solid
          Purity
          >95% by HPLC
          Solubility
          Soluble in DMSO
          Other Properties
          Sequence: Pal-Ser-Gly-Arg-Arg-Tyr-Gly-His-Ala-Leu-Arg-NH2,Pal-SGRRYGHALR-NH2
          Modification: C terminal palmitoylation, N terminal amide
          Storage
          Store dry, frozen and in the dark

          * Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.

    We Also Recommend

    PACAP 27

    $385

    PACAP 38

    $402

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.